Title : Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors.

Pub. Date : 2013 Jun

PMID : 23730503






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Dipeptidyl-peptidase-IV (DPP-4) inhibitors have become an important orally active drug class for the treatment of type 2 diabetes as second-line therapy after metformin failure or as monotherapy or combination therapy with other drugs when metformin is not tolerated or contraindicated. Metformin dipeptidyl peptidase 4 Homo sapiens
2 Dipeptidyl-peptidase-IV (DPP-4) inhibitors have become an important orally active drug class for the treatment of type 2 diabetes as second-line therapy after metformin failure or as monotherapy or combination therapy with other drugs when metformin is not tolerated or contraindicated. Metformin dipeptidyl peptidase 4 Homo sapiens
3 Dipeptidyl-peptidase-IV (DPP-4) inhibitors have become an important orally active drug class for the treatment of type 2 diabetes as second-line therapy after metformin failure or as monotherapy or combination therapy with other drugs when metformin is not tolerated or contraindicated. Metformin dipeptidyl peptidase 4 Homo sapiens
4 Dipeptidyl-peptidase-IV (DPP-4) inhibitors have become an important orally active drug class for the treatment of type 2 diabetes as second-line therapy after metformin failure or as monotherapy or combination therapy with other drugs when metformin is not tolerated or contraindicated. Metformin dipeptidyl peptidase 4 Homo sapiens